

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

Doyel Mitra,¹ Michael J. Brumlik,²
Stella U. Okamgba,¹ Yun Zhu,³
Tamika T. Duplessis,⁴ Jenny G. Parvani,¹
Samuel M. Lesko,⁵ Edi Brogi,⁶ and Frank E. Jones⁷

¹Department of Pathology, University of Colorado-Denver, Aurora, Colorado; ²Cancer Therapy and Research Center, University of Texas Health Center at San Antonio, San Antonio, Texas; Departments of ³Medicine and ⁴Structural and Cellular Biology, Tulane University Health Sciences Center, New Orleans, Louisiana; ⁵Northeast Regional Cancer Institute, Scranton, Pennsylvania; ⁶Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York; and ⁷Department of Cell and Molecular Biology, Tulane University, New Orleans, Louisiana

Abstract

The HER2-targeted therapy trastuzumab is widely used for the treatment of patients with metastatic breast tumors overexpressing HER2. However, an objective response is observed in only 12% to 24% of patients treated with trastuzumab as a single agent and initial responders regress in <6 months (1–3). The reason for the clinical failure of trastuzumab in this setting remains unclear. Here we show that local lymph node–positive disease progression in 89% of breast cancer patients with HER2-positive tumors involves the HER2 oncogenic variant HER2Δ16. We further show that ectopic expression of HER2Δ16, but not wild-type HER2, promotes receptor dimerization, cell invasion, and trastuzumab resistance of NIH3T3 and MCF-7 tumor cell lines. The potentiated metastatic and oncogenic properties of HER2Δ16 were mediated through direct coupling of HER2Δ16 to Src kinase. Cotargeting of HER2Δ16 and Src kinase with the single-agent tyrosine kinase inhibitor dasatinib resulted in Src inactivation, destabilization of HER2Δ16, and suppressed tumorigenicity. Activated Src kinase was also observed in 44% of HER2Δ16-expressing breast carcinomas under-

scoring the potential clinical implications of coupled HER2Δ16 and Src signaling. Our results suggest that HER2Δ16 expression is an important genetic event driving trastuzumab-refractory breast cancer. We propose that successful targeted therapeutics for intervention of aggressive HER2-positive breast cancers will require a strategy to suppress HER2Δ16 oncogenic signaling. One possibility involves a therapeutic strategy employing single-agent tyrosine kinase inhibitors to disengage the functionally coupled oncogenic HER2Δ16 and Src tyrosine kinase pathways. [Mol Cancer Ther 2009;8(8):2152–62]

Introduction

Recent human tumor gene expression profiling initiatives have resulted in the identification of five distinct breast cancer phenotypic subclasses underscoring the complexity of this disease (4–6). Clinical validation of the breast tumor gene expression classification scheme showed that each tumor subclass exhibited distinct clinical outcomes with the HER2/Erbb2/*neu* (HER2)–positive subtype associated with the shortest relapse-free and overall patient survival (6, 7). HER2, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is overexpressed in 20% to 40% of invasive breast cancers and is associated with poor prognosis in these patients (8). Furthermore, HER2-overexpressing tumors exhibit decreased response to adjuvant therapy (9). HER2 overexpression has been the target of several recent clinical interventions. Trastuzumab, a Food and Drug Administration–approved humanized monoclonal antibody directed against the HER2 cell surface receptor, has emerged as an important intervention for patients with HER2-positive tumors. However, the vast majority of patients exhibit *de novo* resistance to single-agent trastuzumab with an objective response observed in only 12% to 24% of patients with HER2-positive tumors and all initial responders develop resistance in <6 months (1–3). Improved patient responses of 40% to 50% are observed when trastuzumab is used in combination with chemotherapy; however, similar to single-agent trastuzumab, many of these patients eventually acquire trastuzumab resistance (10, 11). Early indications from clinical trials of trastuzumab and chemotherapy combinations in the adjuvant setting appear promising with impressive patient response rates, but acquired resistance to trastuzumab remains a serious problem (12, 13).

Molecular events that contribute to trastuzumab resistance have been proposed including inactivation of the PTEN phosphatase resulting in enhanced AKT signaling (14) and suppression of p27^{Kip1}, thus disengaging trastuzumab-induced G₁ cell cycle arrest (15). In addition, a unique insulin-like growth factor receptor-1 and HER2 heterodimer has been detected in trastuzumab-resistant cell lines and disrupting insulin-like growth factor receptor-1/HER2 crosstalk

Received 3/31/09; accepted 5/26/09; published OnlineFirst 8/11/09.

Grant support: Louisiana Cancer Research Consortium and University of Colorado-Denver Department of Pathology.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary material for this article is available at Molecular Cancer Therapeutics Online (<http://mct.aacrjournals.org/>).

This work is dedicated to our dear friend Cindy Morris, another breast cancer patient contending with trastuzumab failure.

Requests for reprints: Frank E. Jones, Department of Cell and Molecular Biology, Tulane University, 6400 Freret Street, 2000 Percival Stern Hall, New Orleans, LA, 70118. Phone: 504-862-8081; Fax: 504-865-6785. E-mail: fjones3@tulane.edu

Copyright © 2009 American Association for Cancer Research.

doi:10.1158/1535-7163.MCT-09-0295

sensitizes resistant cells to trastuzumab (16). Although promising, clinical verification of these molecular findings will be necessary. For example, one recent study failed to detect an association between expression of PTEN or the PTEN target AKT and clinical outcome of breast cancer patients receiving neoadjuvant trastuzumab (17).

Tumor-specific genetic or molecular events that enhance HER2 oncogenic activity and/or affect trastuzumab binding to HER2 may also contribute to trastuzumab resistance. Although the search for a somatic *HER2* oncogenic mutation in HER2-amplified breast tumors has failed to identify a promising activating genetic lesion (18–20), HER2 isoforms that may influence trastuzumab response have been observed in breast tumors. For example, a membrane-associated isoform of HER2 (p95HER2), lacking both the receptor extracellular domain and trastuzumab epitope, has been detected in up to 60% of HER2-positive tumors (21–23). Ectopic expression of p95HER2 results in an actively signaling protein, which in both pre-clinical and clinical studies appears to promote trastuzumab resistance (21, 23). Also of interest is a recently identified HER2 splice variant (HER2 Δ 16) with potent transforming activity, which was originally detected in several HER2-overexpressing breast cancer cell lines (24, 25) and primary tumors (25, 26). When overexpressed in multiple mammalian cell types, HER2 Δ 16 harbors enhanced transforming activity when compared with wild-type HER2 (24, 25). We reasoned that tumor expression of oncogenic HER2 Δ 16 would not only promote aggressive breast cancer but also may be inherently resistant to trastuzumab therapy. The HER2 Δ 16 isoform has not been adequately investigated in this or any clinical setting.

In this report, we show that expression of HER2 Δ 16 is a tumor-specific molecular event and the vast majority of women with tumor expression of HER2 Δ 16 develop locally disseminated node-positive breast cancer. Furthermore, tumor cell lines expressing HER2 Δ 16 are resistant to the HER2-targeted therapy trastuzumab. Our preclinical results suggest that single-agent targeting of tyrosine kinase pathways provides an effective strategy for suppressing HER2 Δ 16 tumorigenesis and trastuzumab resistance.

Materials and Methods

Human Tissues and RNA

Total RNA was extracted from institutional review board-approved normal and malignant breast samples using Trizol reagent (Invitrogen). A Human Total RNA Master Panel II containing RNA from 18 different human tissue sites was obtained from BD Biosciences.

Reverse Transcription-PCR

Reverse transcription-PCR (RT-PCR) was done using standard procedures. Primers to amplify wild-type HER2 were upstream 5'-GTGTGGACCTGGATGACAAGGG and downstream 5'-GCTCCACCAGCTCCGTTTCTG, HER2 Δ 16 were 5'-CACCCACTCCCCTCTGAC spanning the junction between HER2 exons 15 and 17 in HER2 Δ 16 (Fig. 1A) and the downstream primer, or β -actin were 5'-

CAAGGCCAACCGCGAGAAGAT and 5'-GTCCCCGCCA-GCCAGGTCCAG.

Plasmid Constructs

The pcDNA3 HER2 Δ 16 expression plasmid has been described previously (27). Expression plasmid for chicken Src kinase was provided by Sarah Parsons at University of Virginia.

Cell Lines and Transfections

The NIH3T3 and MCF-7 cell lines were purchased from the American Type Culture Collection and cultured according to their instructions. Stable cell lines expressing pcDNA3, pcDNA3-HER2, or pcDNA3-HER2 Δ 16 have been described elsewhere (27). Transfection of cells with nonspecific control or Src kinase RNA interference (RNAi; Dharmacon) was done using methods described elsewhere (28).

Cell Invasion/Migration Assay

Cell invasion/migration was determined using the 24-well BD BioCoat Invasion Chamber with an insert containing an 8 μ m pore size PET membrane with or without Matrigel Basement Membrane Matrix (BD Biosciences). Cells were seeded at 2.5×10^4 per well in medium with 0.2% fetal bovine serum and medium containing 10% fetal bovine serum as a chemotactic. Cells were incubated at 37°C for 22 h and stained with crystal violet.

Cell Proliferation Assay

Cell proliferation was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and/or colony formation assays exactly as described elsewhere (29).

Immunoprecipitation and Western Blot Analysis

Immunoprecipitation and Western blot analysis were done as described previously (30). All antibodies were obtained from Cell Signaling, except HER2 P-Y1248 (Upstate), P-Tyr PY99 (Santa Cruz Biotechnology), P-Tyr 4G10 (Upstate), HER2 (Neomarkers), α -tubulin (Upstate), β -actin (Abcam), goat anti-mouse IRDye 800CW, and goat anti-rabbit IRDye 800CW (Li-Cor).

Nondenaturing PAGE

Total cell lysates were prepared and analyzed by gradient nondenaturing PAGE as described elsewhere (31).

Immunofluorescence and Immunohistochemistry

Deconvolution microscopy and immunofluorescent detection of HER2/HER2 Δ 16 and Src kinase were done exactly as described elsewhere (32) using rabbit anti-HER2 (Lab Vision) with Alexa Fluor 488-conjugated goat anti-rabbit IgG (Molecular Probes) and mouse anti-Src kinase (Invitrogen) with Alexa Fluor 568-conjugated goat anti-mouse IgG (Molecular Probes). Immunohistochemistry of primary human breast tumors for phospho-Src kinase was done essentially as described elsewhere (30) with the addition of an antigen retrieval step by incubating the slides in 100 mmol/L citric buffer (pH 6.2) in a steam chamber for 30 min. Primary antibody was P-Src Y416 (Cell Signaling) used at a 1:100 dilution.

Results

HER2 Δ 16 Is a Tumor-Specific HER2 Oncogenic Isoform

Expression of an oncogenic HER2 splice isoform with an in-frame deletion of exon 16 (HER2 Δ 16) has been noted in




Figure 1. Expression of HER2 and HER2Δ16 in human tissues and breast tumors. **A**, schematic of mRNA from wild-type HER2 and the exon 16 deletion isoform HER2Δ16 with relative positions of RT-PCR primers and predicted size of each PCR-amplified product indicated. **B**, RT-PCR detection of HER2 and HER2Δ16 expression in normal human tissue RNA. **C**, RT-PCR detection of HER2 and HER2Δ16 expression in RNA isolated from normal and malignant breast tissue. Representative examples of tumors with HER2 overexpression (1–3), tumors lacking HER2 overexpression (4–6), and tumors with HER2 and HER2Δ16 overexpression (7–9).

several breast cancer cell lines (24) and most recently in a limited survey of primary breast carcinomas (26). Loss of HER2 exon 16 results in a constitutively active HER2 protein with an in-frame deletion of residues 691 to 707 within one of the ectodomain cysteine-rich regions (24–26). To facilitate detection of HER2Δ16 expression in human tissue samples, we designed a highly sensitive HER2Δ16-specific RT-PCR assay using an oligonucleotide primer that traverses the unique exons 15 and 17 junction of HER2Δ16 (Fig. 1A). For specific RT-PCR of wild-type HER2, we replaced the exon 15/17 primer with an oligonucleotide primer within exon 16 (Fig. 1A). As predicted, the exon 15/17 primer only amplified the 158-bp PCR product from the HER2Δ16 cDNA, whereas the exon 16 primer amplified the predicted 196-bp product from a HER2 cDNA, thereby showing the specificity of our assay (Fig. 1B and C).

We next analyzed HER2 and HER2Δ16 expression in a panel of normal human tissues and primary human breast tumors. Interestingly, we failed to detect HER2Δ16 transcripts in RNA samples from a panel of 18 different normal human tissues (Fig. 1B) including several normal breast samples (Fig. 1B and C). Consistent with other reports, HER2 was expressed at higher levels in normal thyroid, placenta, trachea, kidney, prostate, and mammary gland (Fig. 1B and C; refs. 33, 34). We next analyzed HER2 and HER2Δ16 expression in a patient cohort of 85 primary invasive breast tumors (Supplementary Table S1). The 33 HER2-negative tumors analyzed in this study also lacked HER2Δ16 expression (Fig. 1C). We therefore selected the remainder of our cohort to include only patients with HER2-positive breast tumors. We observed a direct concordance between HER2-positive invasive tumors determined by fluorescent *in situ* hybridization or immunohistochemistry and our RT-PCR expression analysis and all HER2 fluorescent *in situ* hybridization-negative or immunohistochemistry-negative tumors were also negative by RT-PCR (data not shown). We also detected HER2Δ16 expression in 52% (27 of 52) of HER2-positive breast tumors (Fig. 1C; Supplementary Table S2). Amplification by RT-PCR of the HER2Δ16 isoform was confirmed by direct sequencing of the PCR products (data not shown). In summary, HER2Δ16 appears to be a tumor-specific HER2 oncogenic isoform coexpressed with HER2 in nearly half of the HER2-positive invasive breast tumors analyzed in this study.

HER2Δ16 Expression Is Significantly Associated with Lymph Node-Positive Breast Cancer

Expression of HER2 with and without HER2Δ16 expression was compared with common clinicopathologic parameters to identify possible associations. Consistent with numerous published studies, the HER2-negative patients in our cohort tended to have lower-grade tumors and lacked significant associations with lymph node involvement and estrogen receptor status (9). Also consistent with published clinical studies, HER2-positive patients tended to have higher-grade tumors, but once again significant associations between lymph node involvement and estrogen receptor status were not detected (Supplementary Table S2).

To determine the effect of HER2Δ16 expression on clinicopathologic parameters, we divided the HER2-positive patients into two groups based on the presence or absence of HER2Δ16 coexpression. Although patients with HER2-positive and HER2Δ16-negative tumors tended to have higher-grade tumors, we observed a surprising inverse correlation with lymph node involvement with only 12% (3 of 25) of these patients presenting with affected nodes (Supplementary Table S2). In striking contrast, 89% (24 of 27) of patients with HER2-positive tumors coexpressing HER2Δ16 presented with positive lymph nodes. These patients also tended to have higher-grade estrogen receptor-negative tumors (Supplementary Table S2). Positive lymph nodes at the time of diagnosis remains the most reliable clinical predictor of negative prognosis in the breast cancer clinic. The highly significant association of HER2Δ16 expression with positive lymph nodes ($P < 0.0001$) observed in this limited analysis

strongly implicates HER2 Δ 16 as a clinically important and tumor-specific HER2 molecular alteration promoting aggressive locally disseminated metastatic breast cancer.

HER2 Δ 16 Forms Stable Dimers and Couples to Multiple Oncogenic Signaling Pathways

We next compared the signaling activities of wild-type HER2 and HER2 Δ 16 ectopically expressed in the MCF-7 breast cancer cell line. Despite equivalent levels of receptor expression, basal levels of HER2 site-specific and total phosphorylation were greater than HER2 Δ 16 (Fig. 2A). However, nearly all of MCF-7 expressed HER2 Δ 16 was stably dimerized, whereas HER2 was predominantly expressed as a monomer (Fig. 2B), suggesting that HER2 Δ 16 forms a stable constitutively active homodimer. We next determined if the HER2 Δ 16 homodimer coupled with other members of the EGFR family. We examined expression and basal phosphorylation of each EGFR family member in the MCF-7 cell lines. Ectopic expression of HER2 or HER2 Δ 16 resulted in a slight but equivalent increase in EGFR expression and phosphorylation when compared with vector control cells (Fig. 2C). Dramatic activation of HER3 was observed in the HER2 but not the HER2 Δ 16-expressing MCF-7 cells (Fig. 2C). In addition, enhanced expression of HER4 was observed in the HER2 cells, whereas HER2 Δ 16-expressing MCF-7 cells lacked HER4 expression altogether (Fig. 2C; ref. 27). These results indicate that wild-type HER2 and HER2 Δ 16 differentially couple to other EGFR family members, nevertheless it seems unlikely that additional EGFR family members will significantly contribute to HER2 Δ 16 oncogenic activity.

We next determined if HER2 Δ 16 expression resulted in activation of oncogenic signal transduction pathways known to function downstream of constitutively activated HER2, that is, FAK, Src kinase, phosphatidylinositol 3-kinase/AKT, and mitogen-activated protein kinase. Despite high levels of autophosphorylation and an association with activated HER3, ectopic HER2 expression in MCF-7 cells only marginally activated each signal transduction pathway examined (Fig. 2D). In contrast, ectopic HER2 Δ 16 expression resulted in increased activation of multiple oncogenic pathways examined (Fig. 2D).

HER2 Δ 16 Expression Enhances Cell Tumorigenicity

We next compared the biological activities of ectopically expressed HER2 and HER2 Δ 16 in NIH3T3 and MCF-7 cells. Expression of HER2 Δ 16 significantly enhanced the proliferation of NIH3T3 and MCF-7 cells in growth kinetic and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, respectively, whereas HER2 expression failed to affect cell proliferation in these assays (Fig. 3A and B). Both HER2 and HER2 Δ 16 enhanced colony formation of MCF-7 cells (Fig. 3C). Although HER2 Δ 16 expression resulted in an insignificant increase in colony number when compared with HER2-expressing cells, the colonies formed by HER2 Δ 16-expressing MCF-7 cells were significantly larger (Fig. 3C).

We next examined the ability of HER2 and HER2 Δ 16 to promote MCF-7 cell migration and invasion. MCF-7 cells lack the ability to migrate and invade, and as predicted,

MCF-7 cells exhibited minimal activity in the *in vitro* cell migration/invasion assay (Fig. 3D). Although HER2 enhanced the colony formation activity of MCF-7 cells, overexpression of HER2 failed to enhance MCF-7 cell migration or invasion, whereas HER2 Δ 16 dramatically potentiated MCF-7 cell migration and invasion (Fig. 3D). These results suggest that HER2 Δ 16-expressing cells have enhanced metastatic potential and corroborate our clinical observations where HER2 Δ 16 expression was significantly associated with locally disseminated breast cancer (Supplementary Table S2).

HER2 Δ 16-Expressing Cells Are Trastuzumab Resistant

We next determined if HER2 Δ 16 expression influences tumor cell response to the HER2-targeted therapy, trastuzumab. Although the trastuzumab binding site is amino-terminal to the exon 16 deletion of HER2 Δ 16 (Fig. 4A; ref. 35), one report suggests that the HER2 Δ 16 deletion affects trastuzumab binding (26). Using a cell surface immunofluorescence approach, we observe equivalent levels of trastuzumab binding to both HER2 and HER2 Δ 16 at the cell surface of expressing MCF-7 cells. In addition, trastuzumab binding was similar to the binding of a control HER2 polyclonal antibody directed against a HER2 extracellular domain peptide that does not overlap with the trastuzumab binding region (Fig. 4B). These results indicate that trastuzumab binds similarly to HER2 Δ 16 and wild-type HER2 at the cell surface of breast tumor cells.

Trastuzumab treatment of MCF-7/HER2 cells down-regulated wild-type HER2 protein levels and suppressed HER2-mediated signaling in MCF-7 cells to basal levels. Significantly, the PTEN tumor suppressor was dephosphorylated and therefore activated following trastuzumab treatment of HER2-expressing MCF-7 cells (Fig. 4C, *asterisks*). The antitumor activity of dephosphorylated PTEN is emerging as an important mechanism of trastuzumab action (14). Trastuzumab treatment also significantly reduced cell proliferation and colony formation of each HER2-expressing MCF-7 and NIH3T3 cell line (Fig. 4D; Supplementary Fig. S1A). Despite similar levels of trastuzumab-induced HER2 Δ 16 down-regulation, oncogenic signaling was sustained in trastuzumab-treated HER2 Δ 16-expressing cells. Most notably, PTEN remained in the inactive phosphorylated state (Fig. 4C, *asterisks*). Consistent with this sustained oncogenic signaling, HER2 Δ 16-expressing MCF-7 and NIH3T3 cell lines were refractory to trastuzumab treatment in both cell proliferation and invasion assays (Fig. 4D; Supplementary Fig. S1A). Surprisingly, under several experimental conditions, trastuzumab appears to behave as a HER2 Δ 16 agonist and promotes HER2 Δ 16 cell growth and invasion (Fig. 4D; Supplementary Fig. S1A).

HER2 Δ 16 Cooperates with Src Kinase to Promote Cell Invasion

Despite the high levels of autophosphorylation, HER2 only marginally activated the multiple signal transduction pathways examined and each of these pathways was suppressed by trastuzumab treatment. HER2 Δ 16-expressing cells, on the other hand, were trastuzumab-resistant and retained activation of multiple oncogenic and cell invasion


loss of HER2 Δ 16 protein and disengages HER2 Δ 16-mediated cell invasion. We therefore reasoned that a tyrosine kinase inhibitor may directly or indirectly affect both Src kinase and HER2 Δ 16, thereby suppressing HER2 Δ 16 oncogenic activity and reversing therapeutic resistance. The tyrosine kinase inhibitor dasatinib has been recently approved for the treatment of patients with imatinib-refractory leukemias (39, 40). Dasatinib is currently in clinical trials for the treatment of solid tumors and has recently been shown to inhibit the growth and proliferation of multiple breast tumor cell lines (41, 42). Although originally designed as a Src kinase family inhibitor, dasatinib displays broader than anticipated tyrosine kinase inhibitor activity including direct inhibition of receptor tyrosine kinases (42–45).

Considering the potent tyrosine kinase inhibitor activity of dasatinib, we next determined the effect of dasatinib treatment on HER2 Δ 16-expressing cell lines. Dasatinib effectively suppressed the activation of multiple signaling molecules, including Src kinase, at a concentration of 100

nmol/L in each MCF-7 cell line tested (Fig. 6A, *asterisks*). Interestingly, the loss of activated Src was accompanied by a specific and dramatic loss of HER2 Δ 16 protein, whereas HER2 activation and protein levels were only marginally affected by dasatinib treatment (Fig. 6A, *asterisks*). We observed a similar loss of HER2 Δ 16 protein when Src expression was suppressed by RNAi (Fig. 5C). Taken together, these results suggest that Src loss-of-function results in specific destabilization of HER2 Δ 16. We are currently investigating the molecular basis of HER2 Δ 16 destabilization in response to dasatinib.

Consistent with dasatinib-induced suppression of multiple signaling pathways, each cell line tested was sensitive to dasatinib treatment with an IC₅₀ of 10 nmol/L observed for MCF-7 cells and HER2- and HER2 Δ 16-expressing cells were equally sensitive to dasatinib with an IC₅₀ of ~50 nmol/L (Fig. 6B). Furthermore, as a single-agent, dasatinib effectively suppressed cell growth and proliferation in each cell line tested including trastuzumab-resistant

Figure 3. HER2 Δ 16 promotes proliferation and invasion of tumor cells. **A**, cell growth assay of NIH3T3 cells expressing HER2 or HER2 Δ 16. Each cell line was plated in duplicate at 0.5×10^5 cells per plate and cell numbers were counted. *Inset*, Western blot analysis of each stable cell line. **B**, indicated MCF-7 stable cell lines were plated in triplicate in a 96-well plate at 2×10^3 cells per well and a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation assay was done after 7 d using standard procedures. **C**, colony formation assay with each cell line seeded in duplicate into a 6-well plate at 1×10^3 cells per well and incubated for 7 to 10 d. Colony number and size were calculated using a ColCount colony counter (Oxford Optronix). Data are normalized to the MCF-7/pcDNA vector control. Representative colony formation results. **D**, invasion and migration of each stable MCF-7 cell line was determined using a BD BioCoat Invasion Chamber with (invasion) or without (migration) Matrigel insert. Invading/migrating cells were counted after 22 h. **B** to **D**, mean \pm SE. *Asterisk*, HER2 Δ 16 cells significantly different from both vector control and HER2-expressing cells.






Figure 4. HER2 Δ 16 promotes trastuzumab resistance. **A**, schematic of HER2 protein with positions of putative signal peptide (SP), two cysteine-rich regions (cys1 and cys2), transmembrane region (TM), and intracellular tyrosine kinase domain (TK). The exon 16 deletion in HER2 Δ 16 (light gray) is positioned in a region carboxyl to the binding site of trastuzumab. **B**, trastuzumab binds to the cell surface of HER2 Δ 16-expressing MCF-7 cells. Immunofluorescence assay of the indicated stable MCF-7 cell lines showing overlap between cell surface binding of a HER2 polyclonal antibody (red) and the humanized HER2 antibody trastuzumab (green) in both HER2- and HER2 Δ 16-expressing cells. Binding of HER2 antibody or trastuzumab was not observed in the MCF-7/vector control cells. **C**, indicated stable MCF-7 cell lines were treated with 10 μ g/mL trastuzumab for 48 h and protein lysates were analyzed by Western blot. Asterisk, trastuzumab dephosphorylated activation of PTEN in HER2-expressing cells. **D**, HER2 Δ 16-expressing MCF-7 cells are trastuzumab resistant. Each stable MCF-7 cell line was treated with 10 μ g/mL trastuzumab in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay or colony formation assay. Only the invasive HER2 Δ 16 cell line was treated with 10 μ g/mL trastuzumab in an invasion assay using a BD BioCoat Invasion Chamber. Each entire experiment was repeated at least three times. Mean \pm SE of percent inhibition of treated versus untreated cells.

HER2 Δ 16-expressing cells (Fig. 6C; Supplementary Fig. S1A). Significantly, dasatinib also suppressed HER2 Δ 16-mediated cell invasion (Fig. 6C; Supplementary Fig. S1A). The addition of trastuzumab failed to enhance the inhibitory effects of single-agent dasatinib treatments, suggesting that dasatinib alone is sufficient to fully suppress HER2 and HER2 Δ 16 signaling. Taken together, our results indicate that the proliferative and aggressive metastatic properties of trastuzumab-resistant HER2 Δ 16-expressing breast tumor cells can be suppressed by single-agent treatment using the tyrosine kinase inhibitor dasatinib.

Discussion

Patients with HER2-overexpressing breast tumors have a greater tendency to develop incurable and often lethal

metastatic disease. For reasons that are poorly understood, the HER2-targeted therapy trastuzumab fails as a single agent to provide durable response for patients with metastatic breast cancer involving HER2. In fact, up to 88% of these patients exhibited *de novo* resistance to trastuzumab monotherapy (1–3). In this communication, we show that ~90% of women with HER2-positive tumors and locally disseminated disease, and thus candidates for trastuzumab therapy, presented with tumor expression of HER2 Δ 16, an oncogenic isoform of HER2. We further show that HER2 Δ 16 expression is a tumor-specific event that promotes trastuzumab resistance in multiple tumor cell lines. Current clinical procedures for evaluating HER2 in breast cancer patients rely on immunohistochemistry and/or fluorescent *in situ* hybridization. These assays lack the necessary specificity to distinguish between wild-type HER2 and expression of

the trastuzumab-resistant HER2 Δ 16 oncogenic isoform. The high prevalence of covert HER2 Δ 16 expression in patients with aggressive HER2-positive breast cancer may be one reason why the overwhelming majority of these patients fail single-agent trastuzumab therapy.

Several mechanisms of trastuzumab resistance have been proposed including inactivation of PTEN, down-regulation of p27^{Kip1}, HER2 crosstalk with insulin-like growth factor receptor-1, and tumor expression of p95HER2 (14, 15, 21–23, 46). Of these potential markers of trastuzumab response, only PTEN expression has been adequately tested clinically and PTEN expression failed to predict patient response to trastuzumab. Clinical verification of our findings would potentially have a significant effect on the management of patients with HER2-positive breast cancer. Our results suggest that HER2-positive patients can be further stratified into a trastuzumab-resistant population based on HER2 Δ 16 coexpression. We predict that patients expressing HER2 alone may benefit from single-agent trastuzumab, whereas pa-

tients coexpressing HER2 with oncogenic HER2 Δ 16 would require a more aggressive therapeutic regimen. Obtaining clinical support for our hypothesis has been proven difficult. Early single-agent trastuzumab trials were discontinued in favor of trastuzumab and chemotherapy combinations. The insufficient number of available patient tumor RNA samples from single-agent trastuzumab trials has prevented us from evaluating the effect of HER2 Δ 16 expression in these trials.

With the goal of identifying an alternative targeting strategy in HER2 Δ 16-expressing tumor cells, we found that Src kinase is a critical effector of HER2 Δ 16 tumorigenic properties. In fact, Src kinase appears to function as a “master regulator” in our system stabilizing HER2 Δ 16 protein expression and coupling HER2 Δ 16 to multiple mitogenic and cell motility pathways. For example, suppression of Src activity resulted in disengaged mitogen-activated protein kinase and phosphatidylinositol 3-kinase/AKT oncogenic pathways and loss of FAK activation, an essential




Figure 5. HER2 Δ 16 directly couples to Src kinase in breast tumor cells. **A**, immunofluorescent detection of HER2 or HER2 Δ 16 (green) and Src kinase (red) in HER2 Δ 16- and HER2-expressing MCF-7 cells and analyzed by deconvolution microscopy. **B**, Src kinase coimmunoprecipitates with HER2 Δ 16 but not HER2. HEK293T cells were cotransfected with chicken Src kinase and HER2-Flag or HER2 Δ 16-Flag. Src and Flag immunoprecipitates were probed by Western blot for Src kinase or Flag-tagged HER2 and HER2 Δ 16. **C**, suppression of Src kinase destabilizes HER2 Δ 16 and inhibits cell invasion. Invasion assay of MCF-7/HER2 Δ 16 cells using a BD BioCoat Invasion Chamber following treatment with nonspecific (NS) or Src targeting RNAi. Control Western blot showing suppression of Src expression and loss of HER2 Δ 16 protein following treatment with Src RNAi. Asterisks, nonspecific band observed in Src kinase Western blot. **D**, activated Src kinase is coexpressed with HER2 Δ 16 in invasive breast tumors. HER2 Δ 16(+) and HER2 Δ 16(-) primary invasive breast tumors (Supplementary Tables S1 and S2) were stained by immunohistochemistry for activated Src kinase P-Src Y416. Membrane associated and activated Src kinase was observed in 44% (4 of 9) of HER2 Δ 16(+) tumors and 25% (1 of 4) of HER2 Δ 16(-) tumors.




Figure 6. Trastuzumab-resistant HER2Δ16 cells are sensitive to the tyrosine kinase inhibitor dasatinib. **A**, each stable MCF-7 cell line was treated with increasing amounts of dasatinib (0, 10, 100, or 1,000 nmol/L), and after 24 h, protein lysates were analyzed by Western blot. Asterisks, dasatinib-induced suppression of Src kinase and loss of HER2Δ16. **B**, dasatinib dose-response. Each stable MCF-7 cell line was treated with the indicated concentration of dasatinib and viability was determined using a colony formation assay. **C**, trastuzumab-resistant and trastuzumab-sensitive tumor cell lines are sensitive to dasatinib. Each indicated stable MCF-7 cell line was treated with 10 μg/mL trastuzumab and/or 100 nmol/L of the tyrosine kinase inhibitor dasatinib in a colony formation assay and the invasive MCF-7/HER2Δ16 was similarly treated in an invasion assay using a BD BioCoat Invasion Chamber. **B** and **C**, each experiment was repeated at least three times. Mean and \pm SE of percent viability of treated versus untreated cell lines.

mediator of Src promoted cell motility and invasion (36). In addition, Src kinase may contribute to trastuzumab resistance of HER2Δ16-expressing cells through phosphorylated inactivation of the PTEN tumor suppressor (38). We observed both sustained Src activation and PTEN phosphorylation following trastuzumab treatment of resistant HER2Δ16-expressing breast tumor cells. Consistent with other reports, PTEN was dephosphorylated to an active form following trastuzumab treatment of responsive HER2-expressing breast tumor cells (14). As an important clinical correlate, we observed expression of activated Src kinase in a large percentage of HER2Δ16-expressing invasive breast tumors, raising the possibility that coupled HER2Δ16 and Src kinase signaling contributes to trastuzumab-refractory disseminated breast cancer observed clinically.

Preclinical and clinical evidence of cooperation between the oncogenic tyrosine kinases HER2Δ16 and Src to promote breast tumorigenesis implies that treatment with a tyrosine kinase inhibitor may suppress the oncogenic HER2Δ16/Src signaling axis. We investigated the efficacy of the tyrosine kinase inhibitor dasatinib, currently in clinical use for the treatment of patients with refractory leukemias, as a single-agent in our preclinical assays. Although originally designed as a Src kinase family inhibitor, dasatinib appears to have broad tyrosine kinase specificity (43, 45) and effectively inhibits breast tumor cell lines with the most aggressive phenotypes (41, 42). Likewise, dasatinib suppressed each tumor cell line tested here including HER2Δ16-expressing trastuzumab-refractory tumor cell

lines. Dasatinib at a dose of 100 nmol/L was sufficient as a single agent to fully suppress HER2Δ16-expressing cells and the addition of trastuzumab had no effect or only marginally improved responses. Interestingly, dasatinib sensitivity did not appear to correlate with the levels of Src activation in each cell line. Consistent with these findings, Src kinase failed to emerge as a marker predicting dasatinib sensitivity in breast cancer cell lines (41, 42), underscoring the potential broad target specificity of this tyrosine kinase inhibitor (43, 45). Although promising candidates have been identified, the direct mediators of dasatinib action in breast tumor cells remain to be confirmed.

Significantly, we also found that knockdown of Src kinase by RNAi or potent dasatinib inhibition of Src kinase activity resulted in an unexpected and specific loss of HER2Δ16 protein, whereas wild-type HER2 levels were largely unaffected. The exact mechanism triggering HER2Δ16 degradation is under investigation but most likely involves enhanced HER2Δ16 ubiquitination and proteosomal degradation in the absence of Src activation.⁸ Nevertheless, the dramatic preclinical efficacy of dasatinib in HER2Δ16-expressing cells appears to be a result of direct inactivation of Src kinase and subsequent HER2Δ16 destabilization. Interestingly, Src kinase has been shown to phosphorylate Cbl ubiquitin ligase, thereby suppressing Cbl-mediated ubiquitination and proteosomal degradation of EGFR family members (47–50). By inactivating Src kinase, dasatinib

⁸ Mitra D, Parvani JG, Jones FE, unpublished observations.

may reverse Cbl suppression and promote HER2 Δ 16 degradation. The essential contribution of Src kinase to HER2 Δ 16 stability and tumorigenesis and the high prevalence of activated Src observed in HER2 Δ 16-expressing breast carcinomas supports a clinical role for single-agent dasatinib intervention in patients with trastuzumab-resistant HER2 Δ 16-expressing tumors.

In conclusion, our clinical findings indicate that HER2 Δ 16 represents the first highly penetrant HER2 oncogenic alteration identified in human cancer. We propose that the success of therapeutic intervention in HER2-positive breast cancer will require a paradigm shift from the molecular targeting of wild-type HER2 to a strategy that suppresses HER2 Δ 16 oncogenic signaling. One exciting possibility is a therapeutic regimen employing tyrosine kinase inhibitors as single agents to suppress trastuzumab-refractory disease. Because HER2 Δ 16 expression is a tumor-specific oncogenic event, we predict that, in contrast to wild-type HER2, HER2 Δ 16-targeted therapeutics would have few, if any, treatment-induced side effects.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

- Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185^{HER2} monoclonal antibody in patients with HER2/*neu*-overexpressing metastatic breast cancer. *J Clin Oncol* 1996;14:737–44.
- Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol* 1999;17:2639–48.
- Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol* 2002;20:719–26.
- Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiology. *Cancer Cell* 2006;10:529–41.
- Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–52.
- Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001;98:10869–74.
- Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A* 2003;100:8418–23.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/*neu* oncogene. *Science* 1987;235:177–82.
- Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. *J Clin Oncol* 2001;19:2334–56.
- Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. *J Clin Oncol* 2005;23:4265–74.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344:783–92.
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005;353:1659–72.
- Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 2005;353:1673–84.
- Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell* 2004;6:117–27.
- Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. p27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. *Cancer Res* 2004;64:3981–6.
- Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. *Breast Cancer Res* 2006;8:215.
- Yonemori K, Tsuta K, Shimizu C, et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. *Med Oncol* 2008. Published online November 18, 2008. E-pub ahead of print.
- Lee JW, Soung YH, Seo SH, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. *Clin Cancer Res* 2006;12:57–61.
- Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. *Nature* 2004;431:525–6.
- Zito CI, Riches D, Kolmakova J, Simons J, Egholm M, Stern DF. Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer. *Genes Chromosomes Cancer* 2008;47:633–8.
- Anido J, Scaltriti M, Béch Serra JJ, et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. *EMBO J* 2006;25:3234–44.
- Molina MA, Saez R, Ramsey EE, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. *Clin Cancer Res* 2002;8:347–53.
- Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. *J Natl Cancer Inst* 2007;99:628–38.
- Kwong KY, Hung M-C. A novel splice variant of *HER2* with increased transformation activity. *Mol Carcinog* 1998;23:62–8.
- Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. *EMBO J* 1999;18:2149–64.
- Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Menard S. Role of exon-16-deleted HER2 in breast carcinomas. *Endocr Relat Cancer* 2006;13:221–32.
- Narsh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. *Cancer Res* 2008;68:6387–95.
- Narsh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. *Cancer Res* 2006;66:6412–20.
- Zhu Y, Sullivan LL, Nair SS, et al. Coregulation of estrogen receptor by estrogen-inducible ERBB4/HER4 establishes a growth promoting autocrine signal in breast cancer. *Cancer Res* 2006;66:7991–8.
- Jones FE, Welte T, Fu X-Y, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. *J Cell Biol* 1999;147:77–87.
- Siegel PM, Muller WJ. Mutations affecting conserved residues within the extracellular domain of Neu promote receptor dimerization and activation. *Proc Natl Acad Sci U S A* 1996;93:8878–83.
- Williams CC, Allison JG, Vidal GA, et al. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. *J Cell Biol* 2004;167:469–78.
- Haugen DR, Akshen LA, Varhaug JE, Lillehaug JR. Expression of c-erbB-2 protein in papillary thyroid carcinomas. *Br J Cancer* 1992;65:832–7.
- Press MF, Cordon-Cardo C, Slamon DJ. Expression of the *Her-2/neu* proto-oncogene in normal adult and fetal tissues. *Oncogene* 1990;5:953–62.
- Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature* 2003;421:756–60.
- Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. *Oncogene* 2004;23:7928–46.

2162 HER2Δ16 Promotes Trastuzumab Resistance

37. Sandilands E, Cans C, Fincham VJ, et al. RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. *Dev Cell* 2004;7:855–69.
38. Lu Y, Yu Q, Liu JH, et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. *J Biol Chem* 2003;278:40057–66.
39. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. *Blood* 2007;109:2303–9.
40. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *N Engl J Med* 2006;354:2531–41.
41. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing *in vitro*. *Breast Cancer Res Treat* 2007;105:319–26.
42. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. *Cancer Res* 2007;67:2226–38.
43. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. *Nat Biotechnol* 2007;25:1035–44.
44. Chang Q, Jorgensen C, Pawson T, Hedley DW. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. *Br J Cancer* 2008;99:1074–82.
45. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. *Blood* 2007;110:4055–63.
46. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. *Nat Clin Pract Oncol* 2006;3:269–80.
47. Bao J, Gur G, Yarden Y. Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. *Proc Natl Acad Sci U S A* 2003;100:2438–43.
48. Ishizawa R, Parsons SJ. c-Src and cooperating partners in human cancer. *Cancer Cell* 2004;6:209–14.
49. Levkowitz G, Oved S, Klapper LN, et al. c-Cbl is a suppressor of the neu oncogene. *J Biol Chem* 2000;275:35532–9.
50. Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. *Nat Rev Mol Cell Biol* 2001;2:294–307.

Molecular Cancer Therapeutics

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

Doyel Mitra, Michael J. Brumlik, Stella U. Okamgba, et al.

Mol Cancer Ther 2009;8:2152-2162. Published OnlineFirst August 11, 2009.

Updated version Access the most recent version of this article at:
doi:[10.1158/1535-7163.MCT-09-0295](https://doi.org/10.1158/1535-7163.MCT-09-0295)

Supplementary Material Access the most recent supplemental material at:
<http://mct.aacrjournals.org/content/suppl/2009/08/19/1535-7163.MCT-09-0295.DC1>
<http://mct.aacrjournals.org/content/suppl/2016/08/26/1535-7163.MCT-09-0295.DC2>

Cited articles This article cites 49 articles, 26 of which you can access for free at:
<http://mct.aacrjournals.org/content/8/8/2152.full.html#ref-list-1>

Citing articles This article has been cited by 13 HighWire-hosted articles. Access the articles at:
[/content/8/8/2152.full.html#related-urls](http://mct.aacrjournals.org/content/8/8/2152.full.html#related-urls)

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.